Marshall Wace’s Capricor Therapeutics CAPR Stock Holding History

Marshall Wace’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.36M	Sell	98,185 -11,346	-10%	-$344K	﹤0.01%	1764
2026 Q1	$3.33M	Sell	109,531 -12,381	-10%	-$330K	﹤0.01%	1517
2025 Q4	$3.52M	Buy	121,912 +22,799	+23%	+$298K	﹤0.01%	1316
2025 Q3	$715K	Buy	99,113 +18,926	+24%	+$139K	﹤0.01%	2091
2025 Q2	$796K	Buy	+80,187	New	+$847K	﹤0.01%	1946
2025 Q1	–	Sell	-59,303	Closed	-$818K	–	2648
2024 Q4	$818K	Buy	+59,303	New	+$1.04M	﹤0.01%	1823
2024 Q3	–	Sell	-89,314	Closed	-$426K	–	2538
2024 Q2	$426K	Buy	+89,314	New	+$498K	﹤0.01%	2019
2023 Q1	–	Sell	-28,359	Closed	-$109K	–	2695
2022 Q4	$109K	Buy	+28,359	New	+$135K	﹤0.01%	2779

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Marshall Wace's CAPR Position: Q2 2026 in Review

Marshall Wace reduced its Capricor Therapeutics (CAPR) stake by 10% in Q2 2026, selling an estimated $344K and leaving 98,185 shares worth $2.36M. The position accounts for ﹤0.01% of the portfolio, ranked #1764.

Marshall Wace first reported a position in CAPR in Q4 2022 and has held it in 8 quarters since. The position peaked at $3.52M in Q4 2025. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

Marshall Wace held 98,185 shares of Capricor Therapeutics worth $2.36M as of Q2 2026.
Marshall Wace sold 11,346 Capricor Therapeutics shares in Q2 2026, an estimated $344K.
Capricor Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1764 holding.
Marshall Wace first reported a position in Capricor Therapeutics in Q4 2022 and has held it in 8 quarters since.
Marshall Wace's Capricor Therapeutics position peaked at $3.52M in Q4 2025.
169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.